Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jun 6;30(7):1913–1922. doi: 10.1038/s41591-024-03044-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 1 — Consort diagram of 470 patients consented in the PRISM study between Sep 2017 and Dec 2020. 384 patients were eligible for outcome analysis. * ineligible due to non-high-risk cancer diagnosis, lack of appropriate sample or death prior to presentation at the molecular tumour board. ** ineligible due to treatment duration <4 weeks, disease progression within the first 4 weeks of treatment or no response evaluation. *** not evaluable for OCB due to cessation of treatment before 24 weeks in the absence of disease progression where stable disease was best response. CR, complete remission; OCB, objective clinical benefit; OR, objective response of measurable disease; PGT, precision-guided treatment; PFS, progression-free survival.